By Klaus Rose
With the emergence of effective drugs and observed drug toxicities in babies, two mantras emerged: that children are therapeutic orphans, and that children are not small adults. US and EU laws demand pediatric studies as a condition for the approval of new drugs in adults. This is called “Pediatric Drug Development” (PDD). Although apparently reasonable, there are catches. Children are vulnerable at birth, but they grow and become bodily mature with puberty, well before coming of age. Minors are not another species. The 18th birthday, an administrative/ legal limit, does not correspond to a physiological change. Drugs treat the body, not the legal status. PDD results in pointless studies in bodily mature adolescents, and in exaggerated studies in younger minors. An originally well-intentioned concept results in thousands of questionable studies worldwide.
This book draws attention to conflicts of interest and ethical dilemmas of PDD and questions its applicability for adolescents and minors that are no longer babies.
Product Details
Publisher : Ethics International Press, Inc; First Edition (May 17, 2023)
Language : English
Hardcover : 306 pages
ISBN-10 : 1804411353
ISBN-13 : 978-1804411353
Reading age : 12 years and up

Ocular Surface Disease: Cornea, Conjunctiva and Tear Film
Spencer's Pathology of the Lung 6th, 2 Part Set
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12th Edition
Antibiotic Basics for Clinicians: The ABCs of Choosing the Right Antibacterial Agent 2nd
Psychological Insights for Understanding COVID-19 and Media and Technology (PDF)
Sexually Transmitted Infections: Diagnosis, Management, and Treatment
Head and Neck Cancer: An Evidence-Based Team Approach
Telemedicine and Electronic Medicine 


Reviews
There are no reviews yet.